Noubar Afeyan Sells 10,000 Shares of Moderna, Inc. (NASDAQ:MRNA) Stock

Moderna, Inc. (NASDAQ:MRNAGet Rating) Director Noubar Afeyan sold 10,000 shares of the stock in a transaction dated Wednesday, January 18th. The shares were sold at an average price of $200.20, for a total transaction of $2,002,000.00. Following the sale, the director now directly owns 2,247,209 shares of the company’s stock, valued at $449,891,241.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Noubar Afeyan also recently made the following trade(s):

  • On Wednesday, January 11th, Noubar Afeyan sold 10,000 shares of Moderna stock. The shares were sold at an average price of $188.57, for a total transaction of $1,885,700.00.
  • On Wednesday, January 4th, Noubar Afeyan sold 10,000 shares of Moderna stock. The shares were sold at an average price of $182.15, for a total transaction of $1,821,500.00.
  • On Wednesday, December 21st, Noubar Afeyan sold 10,000 shares of Moderna stock. The shares were sold at an average price of $201.70, for a total transaction of $2,017,000.00.
  • On Wednesday, December 14th, Noubar Afeyan sold 10,000 shares of Moderna stock. The stock was sold at an average price of $195.00, for a total transaction of $1,950,000.00.
  • On Wednesday, December 7th, Noubar Afeyan sold 10,000 shares of Moderna stock. The stock was sold at an average price of $172.16, for a total transaction of $1,721,600.00.
  • On Wednesday, November 30th, Noubar Afeyan sold 10,000 shares of Moderna stock. The stock was sold at an average price of $173.52, for a total transaction of $1,735,200.00.
  • On Wednesday, November 23rd, Noubar Afeyan sold 10,000 shares of Moderna stock. The stock was sold at an average price of $178.01, for a total transaction of $1,780,100.00.
  • On Wednesday, November 16th, Noubar Afeyan sold 10,000 shares of Moderna stock. The stock was sold at an average price of $184.25, for a total transaction of $1,842,500.00.
  • On Wednesday, November 9th, Noubar Afeyan sold 10,000 shares of Moderna stock. The stock was sold at an average price of $162.50, for a total transaction of $1,625,000.00.
  • On Wednesday, November 2nd, Noubar Afeyan sold 10,000 shares of Moderna stock. The stock was sold at an average price of $154.20, for a total transaction of $1,542,000.00.

Moderna Stock Up 1.9 %

NASDAQ MRNA opened at $193.98 on Friday. Moderna, Inc. has a 52 week low of $115.03 and a 52 week high of $217.25. The company has a quick ratio of 1.80, a current ratio of 2.10 and a debt-to-equity ratio of 0.05. The business’s fifty day simple moving average is $185.39 and its 200-day simple moving average is $160.95. The firm has a market cap of $74.52 billion, a PE ratio of 7.02 and a beta of 1.71.

Moderna (NASDAQ:MRNAGet Rating) last posted its quarterly earnings results on Thursday, November 3rd. The company reported $2.53 EPS for the quarter, missing the consensus estimate of $3.04 by ($0.51). Moderna had a return on equity of 70.03% and a net margin of 55.00%. The company had revenue of $3.36 billion for the quarter, compared to analysts’ expectations of $3.33 billion. As a group, equities analysts anticipate that Moderna, Inc. will post 21.16 earnings per share for the current year.

Analyst Upgrades and Downgrades

MRNA has been the topic of a number of analyst reports. Piper Sandler raised their price objective on shares of Moderna from $214.00 to $217.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 20th. Chardan Capital raised their price objective on shares of Moderna from $191.00 to $208.00 and gave the stock a “neutral” rating in a research note on Wednesday. SVB Leerink raised their price objective on shares of Moderna from $102.00 to $111.00 and gave the stock a “market perform” rating in a research note on Wednesday. Morgan Stanley lifted their price target on shares of Moderna from $170.00 to $209.00 and gave the company an “equal weight” rating in a research note on Friday, December 16th. Finally, Cowen dropped their price target on shares of Moderna from $165.00 to $145.00 in a research note on Thursday, October 20th. Five equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $191.92.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of MRNA. DAVENPORT & Co LLC purchased a new stake in Moderna in the 4th quarter valued at about $268,000. Veriti Management LLC raised its holdings in Moderna by 37.1% in the 4th quarter. Veriti Management LLC now owns 2,781 shares of the company’s stock valued at $500,000 after buying an additional 753 shares during the period. Clear Harbor Asset Management LLC purchased a new stake in Moderna in the 4th quarter valued at about $202,000. Vestmark Advisory Solutions Inc. acquired a new position in Moderna in the 4th quarter valued at about $229,000. Finally, Hellman Jordan Management Co. Inc. MA grew its position in Moderna by 9.3% in the 4th quarter. Hellman Jordan Management Co. Inc. MA now owns 6,073 shares of the company’s stock valued at $1,091,000 after acquiring an additional 516 shares in the last quarter. Hedge funds and other institutional investors own 63.11% of the company’s stock.

Moderna Company Profile

(Get Rating)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

See Also

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.